Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes.
Philip C M AuKathryn C B TanBernard M Y CheungIan C K WongHang-Long LiChing-Lung CheungPublished in: The Journal of clinical endocrinology and metabolism (2022)
Compared to DPP4is, SGLT2is use was associated with reduced risks of ESRD and ARF, and a slower eGFR decline in a real-world setting. The associations remained statistically significant in patients with or without preindex rapid eGFR decline.